Daniel has been leading our clinical development program in oncology with shared responsibilities in neurology since August 2018. He joined Alector from Genentech Pharma Development Oncology, where he was Associate Group Medical Director from November 2015 to July 2018 leading global development of a small molecule signalling pathway inhibitor for the treatment of cancer. Prior to that time, he served as Medical Director in Oncology Early Clinical Development in gRED from May 2010 to October 2015, overseeing antibody drug conjugate development across the early stage solid tumor programs. Daniel served as Director of Clinical Development at Nektar from January 2009 to April 2010, evaluating pegylated-cytotoxic agents. Previously, he was Director of Clinical Research at Cell Genesys from July 2004 to December 2008, with increasing roles in responsibility engaged in clinical development of immunotherapeutics derived from oncolytic adenovirus, as well as autologous and allogeneic cell constructs. Daniel is a board certified oncologist in the United States. He holds an M.D. and fellowship training from the University of California San Francisco.